1 / 16

Case Study 1

Case Study 1. 55-year-old man is referred for mild lymphadenopathy and lymphocytosis found during routine medical examination. Findings: Patient has 2-3 cm bilateral adenopathy in cervical and axillary chains Spleen and liver are not palpable

silas-castro
Télécharger la présentation

Case Study 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Case Study 1 55-year-old man is referred for mild lymphadenopathy and lymphocytosis found during routine medical examination • Findings: • Patient has 2-3 cm bilateral adenopathy in cervical and axillarychains • Spleen and liver are not palpable • Patient is asymptomatic except for occasional night sweats • Performance score is excellent • CBC count: • WBC count 36,000/µL (79% mature lymphocytes, ANC 2,800 cells/mm3) • Hgb 12.5 g/dL • Platelets 167,000/µL • Flow cytometry consistent with CLL CBC, complete blood cell; WBC, white blood cell; ANC, absolute neutrophil count; Hgb, hemoglobin.

  2. Question 1 What treatment would you recommend for initial therapy? • Observation • Chlorambucil ± prednisone • Chlorambucil + obinutuzumab • Fludarabine + rituximab • Bendamustine + rituximab • Fludarabine, cyclophosphamide + rituximab • Pentostatin, cyclophosphamide + rituximab

  3. Case Study 1 (cont.) • The patient is observed for the next 2 years then progressive fatigue and dyspnea on exertion develop • CBC: • WBC 96,000/µL (87% mature lymphocytes, ANC 4,500 cells/mm3) • Hgb 9.5 g/dL • Platelets 87,000/µL • Evaluation for hemolysis and ITP is negative • No evidence of GI blood loss • Cytotoxic therapy is started • Patient is now 60 years old CBC, complete blood cell; WBC, white blood cell; ANC, absolute neutrophil count; Hgb, hemoglobin; ITP, idiopathic thrombocytopenic purpura.

  4. Question 2 Prior to starting therapy, which of the following prognostic tests would be most important to perform? • None; the patient progressed quickly so we know his prognosis is limited • β2-microglobulin • IgVH mutational status • ZAP-70 status • FISH analysis • CD38 expression IgVH, immunoglobulin heavy chain variable; ZAP-70, zeta-chain–associated protein kinase 70; FISH, fluorescence in situ hybridization.

  5. Case Study 1 (cont.) • FISH analysis is performed and shows del(11q) in 57% and del(17p) in 6% of cells FISH, fluorescence in situ hybridization.

  6. Question 3 What treatment would you recommend at this time? • Observation • Chlorambucil ± prednisone • Chlorambucil + obinutuzumab • Alemtuzumab ± rituximab • Fludarabine + rituximab • Bendamustine + rituximab • Fludarabine, cyclophosphamide, + rituximab • Pentostatin, cyclophosphamide ,+ rituximab

  7. Case Study 1 (cont.) • The patient is treated with FCR and achieves a partial response • The patient does well for the next 18 months, but then progresses and symptomatic anemia requiring therapy develops again • The patient is now 62 years old • Prior to retreatment, FISH analysis was performed and shows del(11q) in 27% and del(17p) in 86% of cells • FCR, fludarabine, cyclophosphamide, + rituximab; FISH, fluorescence in situ hybridization.

  8. Question 4 What treatment would you recommend for second line? • Observation • Chlorambucil + obinutuzumab • Alemtuzumab ± rituximab • Fludarabine + rituximab • Bendamustine + rituximab • Fludarabine, cyclophosphamide, + rituximab • Pentostatin, cyclophosphamide ,+ rituximab • Ibrutinib

  9. Case Study 2 76-year-old woman with diabetes and chronic stable angina • Referred for mild lymphadenopathy and lymphocytosis found during annual medical exam • Findings: • 2 cm adenopathy in the cervical, axillary, and inguinal chains • Spleen is palpable 4 cm below left costal margin • Completely asymptomatic • Performance score is good • CBC count • WBC count 23,000/µL (81% mature lymphocytes, ANC 3,500 cells/mm3) • Hgb 13 g/dL • Platelets 181,000/µL • Flow cytometry is consistent with CLL • FISH analysis shows del 13qin 52% of cells, unmutated • β2-microglobulin of 3.4 µg/mL, negative for ZAP-70 CBC, complete blood cell; WBC, white blood cell; ANC, absolute neutrophil count; Hgb, hemoglobin; FISH, fluorescence in situ hybridization; ZAP-70, zeta-chain–associated protein kinase 70.

  10. Question 1 What treatment would you recommend for initial therapy? • Observation • Chlorambucil ± prednisone • Chlorambucil + obinutuzumab • Fludarabine + rituximab • Bendamustine + rituximab • Fludarabine, cyclophosphamide, + rituximab • Pentostatin, cyclophosphamide, + rituximab

  11. Case Study 2 (cont.) • Patient is observed for the next 6 years • Eventually progressive fatigue and dyspnea on exertion develops; she is now 82 years old • Patient had a mild stroke 2 years ago but has largely recovered • CBC count now shows: • WBC count 126,000/µL (91% mature lymphocytes, ANC 6,300 cells/mm3) • Hgb 8.9 g/dL • Platelets 107,000/µL • Evaluation for hemolysis is negative • There is no evidence of GI blood loss • FISH analysis repeated prior to starting therapy, showed del(13q) in 68% of cells • Together with the patient, it has been decided it is time to start cytotoxic therapy CBC, complete blood cell; WBC, white blood cell; ANC, absolute neutrophil count; Hgb, hemoglobin; FISH, fluorescence in situ hybridization.

  12. Question 2 What treatment would you recommend at this time? • Observation • Chlorambucil ± prednisone • Chlorambucil + obinutuzumab • Fludarabine + rituximab • Bendamustine + rituximab • Fludarabine, cyclophosphamide, + rituximab • Pentostatin, cyclophosphamide,+ rituximab

  13. Case Study 2 (cont.) • Patient is treated with chlorambucil and obinutuzumab and achieves a high-quality partial response • She does well for the next 3 years but symptomatic anemia that does not respond to treatment ultimately develops • Patient is now 84 years old with an ECOG PS of 2 ECOG = Eastern Cooperative Oncology Group.

  14. Question 3 Prior to retreatment, which of the following prognostic tests would be most important to perform? • None; at relapse in an older patient, these tests have little practical utility • β2-microglobulin • IgVH mutational status • ZAP-70 status • FISH analysis • CD38 expression IgVH, immunoglobulin heavy chain variable; ZAP-70, zeta-chain–associated protein kinase 70; FISH, fluorescence in situ hybridization.

  15. Question 4 What treatment would you recommend for second line? • Observation • Chlorambucil + obinutuzumab • Alemtuzumab ± rituximab • Fludarabine + rituximab • Bendamustine + rituximab • Fludarabine, cyclophosphamide, + rituximab • Pentostatin, cyclophosphamide, + rituximab • Idelalisib + rituximab • Ibrutinib

  16. Case Study 2 (cont.) • The patient is treated with ibrutinib • She shows improvement in anemia and lymphadenopathy, and otherwise has stable disease

More Related